Delving into the Latest Updates on Suzhou Hemeijia Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

PDE4(Phosphodieterase 4)	1

Primary objective: To evaluate the safety and tolerability of a single oral dose of different LS21031 capsules in healthy participants. Secondary objective: To evaluate the pharmacokinetic characteristics of the parent compound and metabolites of LS21031 after a single oral dose in healthy participants.

Start Date10 Mar 2026

Sponsor / Collaborator

Suzhou Hemeijia Pharmaceutical Co., Ltd.

[+1]

100 Clinical Results associated with Suzhou Hemeijia Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Suzhou Hemeijia Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Suzhou Hemeijia Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Suzhou Hemeijia Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 May 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1

1

Login to view more data